false
OasisLMS
ar,be,bn,zh-CN,zh-TW,en,fr,de,hi,it,ja,ko,pt,ru,es,sw,vi
Catalog
An Evolving Frontier: Endometrial Cancer Treatment
The Evolving Treatment Landscape for The Managemen ...
The Evolving Treatment Landscape for The Management of Endometrial Cancer
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, Dr. Ramaz Iskander discusses novel treatment options for advanced stage or recurrent endometrial cancer. He highlights the recent advancements in the treatment landscape, including immunotherapy, immunotherapy plus chemotherapy, and antibody drug conjugates. He emphasizes the importance of molecular classification in guiding treatment strategies and discusses the different molecular subgroups of endometrial cancer. Dr. Iskander presents data from several clinical trials, such as NRG GY018, RUBY, and DOE, which have shown the efficacy of immunotherapy in the DMMR and PMMR populations. He also mentions the potential benefits of anti-HER2 therapy, DNA damage repair inhibitors, and hormonal therapy. Additionally, he briefly discusses the use of antibody drug conjugates targeting TROP2 and FR-alpha in endometrial cancer. Dr. Iskander concludes by emphasizing the need for further research and clinical trials to validate these treatment options and improve outcomes for patients with endometrial cancer.
Keywords
endometrial cancer
treatment options
immunotherapy
molecular classification
clinical trials
improve outcomes
×